Should I buy or sell Masimo stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MASI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MASI, but not buy additional shares or sell existing shares. View MASI analyst ratings or view top-rated stocks .

What is Masimo's stock price target for 2024?

7 Wall Street research analysts have issued 12 month price targets for Masimo's shares. Their MASI share price targets range from $86.00 to $170.00. On average, they expect the company's stock price to reach $137.43 in the next year. This suggests that the stock has a possible downside of 0.2%. View analysts price targets for MASI or view top-rated stocks among Wall Street analysts .

How have MASI shares performed in 2024?

Masimo's stock was trading at $117.21 on January 1st, 2024. Since then, MASI shares have increased by 17.4% and is now trading at $137.64. View the best growth stocks for 2024 here .

When is Masimo's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our MASI earnings forecast .

How were Masimo's earnings last quarter?

Masimo Co. (NASDAQ:MASI) issued its quarterly earnings results on Tuesday, February, 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, beating the consensus estimate of $0.82 by $0.43. The medical equipment provider earned $548.90 million during the quarter, compared to analysts' expectations of $545.69 million. Masimo had a trailing twelve-month return on equity of 13.77% and a net margin of 3.98%. The company's revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.32 EPS.

What ETFs hold Masimo's stock?

ETFs with the largest weight of Masimo (NASDAQ:MASI) stock in their portfolio include Simplify Health Care ETF (PINK) , Fidelity Disruptive Medicine ETF (FMED) , First Trust Indxx Medical Devices ETF (MDEV) , Global X Telemedicine & Digital Health ETF (EDOC) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) , SPDR S&P Health Care Equipment ETF (XHE) , Harbor Health Care ETF (MEDI) and BlackRock Future Health ETF (BMED) .

What guidance has Masimo issued on next quarter's earnings?

Masimo updated its FY24 earnings guidance on Friday, March, 22nd. The company provided earnings per share (EPS) guidance of $3.44-3.60 for the period. The company issued revenue guidance of $2.045-2.165 billion.

What is Joe E. Kiani's approval rating as Masimo's CEO?

136 employees have rated Masimo Chief Executive Officer Joe E. Kiani on Glassdoor.com . Joe E. Kiani has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Masimo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA) , Netflix (NFLX) , Shopify (SHOP) , Okta (OKTA) , PayPal (PYPL) , Alibaba Group (BABA) , Mastercard (MA) , Trade Desk (TTD) , Walt Disney (DIS) and Twilio (TWLO) .

Who are Masimo's major shareholders?

Masimo's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Cardinal Capital Management (0.03%), Juncture Wealth Strategies LLC (0.00%) and Riverview Trust Co (0.00%). Insiders that own company stock include Adam Mikkelson , Joe E Kiani , Micah W Young and Tao Levy . View institutional ownership trends .

How do I buy shares of Masimo?

Shares of MASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MASI

Masimo (MASI) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free MASI Stock Alerts

$137.19

-0.92 (-0.67%)

(As of 02:37 PM ET)

Compare

Today's Range: $135.70
▼
$138.24
50-Day Range: $126.49
▼
$146.85
52-Week Range: $75.22
▼
$198.00

Volume: 206,140 shs
Average Volume: 587,432 shs
Market Capitalization: $7.26 billion

P/E Ratio: 90.85
Dividend Yield: N/A
Price Target: $137.43

Get Masimo alerts:

Masimo MarketRank™ Stock Analysis

Analyst Rating: Hold
2.43 Rating Score
Upside/Downside: 0.2% Downside
$137.43 Price Target
Short Interest: Healthy
8.67% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.86
Upright™ Environmental Score
News Sentiment: 0.59
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 7.98%
From $3.51 to $3.79 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.94 out of 5 stars

Medical Sector

214th out of 930 stocks

Electromedical Equipment Industry

4th out of 19 stocks

2.2

Analyst's Opinion

Consensus Rating
Masimo has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Masimo has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
8.67% of the float of Masimo has been sold short.
Short Interest Ratio / Days to Cover
Masimo has a short interest ratio ("days to cover") of 7.
Change versus previous month
Short interest in Masimo has recently decreased by 9.03%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Masimo does not currently pay a dividend.
Dividend Growth
Masimo does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Masimo has received a 61.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "ECG monitors" product. See details.
Environmental Sustainability
The Environmental Impact score for Masimo is -0.86.

2.0

News and Social Media Coverage

News Sentiment
Masimo has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Masimo this week, compared to 10 articles on an average week.
Search Interest
Only 4 people have searched for MASI on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Masimo to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Masimo insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.70% of the stock of Masimo is held by insiders.
Percentage Held by Institutions
85.96% of the stock of Masimo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Masimo are expected to grow by 7.98% in the coming year, from $3.51 to $3.79 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Masimo is 91.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.86.
Price to Earnings Ratio vs. Sector
The P/E ratio of Masimo is 91.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 194.48.
Price to Book Value per Share Ratio
Masimo has a P/B Ratio of 5.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About Masimo Stock (NASDAQ:MASI)

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

MASI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MASI Stock News Headlines

April 16, 2024 | businesswire.com

Masimo Founder and CEO Joe Kiani to Speak on AI at Global Patient Safety Summit in Chile

April 16, 2024 | americanbankingnews.com

Masimo (NASDAQ:MASI) Upgraded to Buy at Stifel Nicolaus

April 16, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.

April 16, 2024 | msn.com

Stifel Upgrades Masimo (MASI)

April 15, 2024 | markets.businessinsider.com

Forecasting The Future: 6 Analyst Projections For Masimo

April 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Masimo: Strategic Developments and Positive Outlook Signal Growth

April 14, 2024 | finance.yahoo.com

Is There An Opportunity With Masimo Corporation's (NASDAQ:MASI) 24% Undervaluation?

April 10, 2024 | forbes.com

Masimo To Explore Spin-Off Of Its Consumer Unit

April 16, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

April 8, 2024 | finance.yahoo.com

Another proxy battle unfolds in the health tech industry

April 5, 2024 | finance.yahoo.com

Apple asks US appeals court to reverse Apple Watch import ban

April 2, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Masimo Amid Strategic Split and Enhanced Profitability Outlook

April 2, 2024 | msn.com

Masimo CEO: Politan wants to oust me

April 1, 2024 | finance.yahoo.com

Masimo faces another proxy challenge from Politan Capital

April 1, 2024 | finance.yahoo.com

Masimo Responds to Politan Capital’s Nomination of Director Candidates and Refutes Politan’s False Claims

March 29, 2024 | msn.com

Masimo’s Proxy Battle Amid Spinoff Potential Spurs 10% Surge in Shares

March 28, 2024 | finance.yahoo.com

Can Mixed Fundamentals Have A Negative Impact on Masimo Corporation (NASDAQ:MASI) Current Share Price Momentum?

March 27, 2024 | msn.com

Activist Politan seeks more seats on Masimo's board to boost presence

March 26, 2024 | finance.yahoo.com

Company News for Mar 26, 2024

March 26, 2024 | wsj.com

Masimo Stock Rises After Report That Activist Investor Seeks More Board Seats

March 26, 2024 | msn.com

Wells Fargo upgrades Masimo to overweight, cites spinoff plan

March 25, 2024 | bloomberg.com

Activist Investor Politan Seeks Two More Board Seats at Masimo

March 25, 2024 | markets.businessinsider.com

Analyst Scoreboard: 5 Ratings For Masimo

March 25, 2024 | msn.com

Masimo May Look at Joint Venture for Consumer Split, CEO Says

March 25, 2024 | msn.com

Activist investor Politan plans second fight at Masimo, sending shares up 5%

March 25, 2024 | marketwatch.com

Masimo’s stock gains on report of activist campaign, disclosure of spinoff plan

March 25, 2024 | gurufocus.com

Masimo (MASI) Explores Splitting Consumer Business, Confirms Financial Guidance

See More Headlines

Receive MASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Masimo and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Electromedical equipment
Sub-Industry: Health Care Equipment
Current Symbol: NASDAQ:MASI
CUSIP: 57479510
CIK: 937556
Web: www.masimo.com
Phone: (949) 297-7000
Fax: 949-297-7001
Employees: 5,200
Year Founded: 1989

Price Target and Rating

Average Stock Price Target: $137.43
High Stock Price Target: $170.00
Low Stock Price Target: $86.00
Potential Upside/Downside: 0.0%
Consensus Rating: Hold
Rating Score (0-4): 2.43
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.51
Trailing P/E Ratio: 91.03
Forward P/E Ratio: 39.16
P/E Growth: N/A
Net Income: $81.50 million
Net Margins: 3.98%
Pretax Margin: 4.30%
Return on Equity: 13.77%
Return on Assets: 5.98%

Debt

Debt-to-Equity Ratio: 0.64
Current Ratio: 2.18
Quick Ratio: 1.22

Sales & Book Value

Annual Sales: $2.05 billion
Price / Sales: 3.55
Cash Flow: $5.74 per share
Price / Cash Flow: 23.93
Book Value: $25.79 per share
Price / Book: 5.33

Miscellaneous

Outstanding Shares: 52,910,000
Free Float: 47,780,000
Market Cap: $7.27 billion
Optionable: Optionable
Beta: 0.97

Social Links

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Joseph E. Kiani (Age 59)
Founder, CEO & Chairman
Comp: $3.31M
Mr. Micah Young (Age 45)
Executive VP & CFO
Comp: $1.13M
Mr. Bilal Muhsin (Age 43)
Chief Operating Officer
Comp: $1.2M
Mr. Thomas Samuel McClenahan (Age 51)
Executive VP, General Counsel & Corporate Secretary
Comp: $957.51k
Mr. Tao Leopold Levy (Age 50)
Executive Vice President of Business Development
Comp: $798.52k
Mr. Paul Hataishi (Age 49)
Senior VP & Chief Accounting Officer
Mr. Yongsam Lee (Age 59)
Executive VP & Chief Information Officer
Comp: $1.1M
Dr. Steven J. Barker (Age 79)
Chairman of Scientific Advisory Board & Chief Science Officer
Comp: $139.56k
Mr. Eli Kammerman
Vice President of Business Development & Investor Relations
Mr. Jon Coleman (Age 60)
President of Worldwide Sales, Professional Services & Medical Affairs
Comp: $584.59k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MASI Stock Analysis - Frequently Asked Questions

Should I buy or sell Masimo stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MASI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MASI, but not buy additional shares or sell existing shares.
View MASI analyst ratings or view top-rated stocks.
What is Masimo's stock price target for 2024?: 7 Wall Street research analysts have issued 12 month price targets for Masimo's shares. Their MASI share price targets range from $86.00 to $170.00. On average, they expect the company's stock price to reach $137.43 in the next year. This suggests that the stock has a possible downside of 0.2%.
View analysts price targets for MASI or view top-rated stocks among Wall Street analysts.
How have MASI shares performed in 2024?: Masimo's stock was trading at $117.21 on January 1st, 2024. Since then, MASI shares have increased by 17.4% and is now trading at $137.64.
View the best growth stocks for 2024 here.
When is Masimo's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MASI earnings forecast.
How were Masimo's earnings last quarter?: Masimo Co. (NASDAQ:MASI) issued its quarterly earnings results on Tuesday, February, 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, beating the consensus estimate of $0.82 by $0.43. The medical equipment provider earned $548.90 million during the quarter, compared to analysts' expectations of $545.69 million. Masimo had a trailing twelve-month return on equity of 13.77% and a net margin of 3.98%. The company's revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.32 EPS.
What ETFs hold Masimo's stock?: ETFs with the largest weight of Masimo (NASDAQ:MASI) stock in their portfolio include Simplify Health Care ETF (PINK), Fidelity Disruptive Medicine ETF (FMED), First Trust Indxx Medical Devices ETF (MDEV), Global X Telemedicine & Digital Health ETF (EDOC), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), SPDR S&P Health Care Equipment ETF (XHE), Harbor Health Care ETF (MEDI) and BlackRock Future Health ETF (BMED).

What guidance has Masimo issued on next quarter's earnings?: Masimo updated its FY24 earnings guidance on Friday, March, 22nd. The company provided earnings per share (EPS) guidance of $3.44-3.60 for the period. The company issued revenue guidance of $2.045-2.165 billion.
What is Joe E. Kiani's approval rating as Masimo's CEO?: 136 employees have rated Masimo Chief Executive Officer Joe E. Kiani on Glassdoor.com. Joe E. Kiani has an approval rating of 90% among the company's employees.
What other stocks do shareholders of Masimo own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Netflix (NFLX), Shopify (SHOP), Okta (OKTA), PayPal (PYPL), Alibaba Group (BABA), Mastercard (MA), Trade Desk (TTD), Walt Disney (DIS) and Twilio (TWLO).
Who are Masimo's major shareholders?: Masimo's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Cardinal Capital Management (0.03%), Juncture Wealth Strategies LLC (0.00%) and Riverview Trust Co (0.00%). Insiders that own company stock include Adam Mikkelson, Joe E Kiani, Micah W Young and Tao Levy.
View institutional ownership trends.
How do I buy shares of Masimo?: Shares of MASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MASI) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial